clinical trial · NCT07246564
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL·phase4·recruiting·n = 40
Myasthenia GravisRozanolixizumab
brief summary
The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
started
Dec 1, 2025
primary completion
Oct 15, 2027
completion
Oct 15, 2027
last updated
Mar 27, 2026
official title
An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol